VERA - Vera Therapeutics' Kidney Disease Drug Has Opportunity In A Competitive Development Landscape: Analyst | Benzinga
Raymond James initiated coverage on Vera Therapeutics Inc (NASDAQ: VERA), a late-stage drug developer in the autoimmune kidney space. The lead asset, atacicept, is a BLyS/APRIL dual inhibitor fusion protein currently in a Phase 3 study in IgA Nephropathy (IgAN).
In June, Vera Therapeutics announced that the Phase 2b ORIGIN trial of atacicept for IgA nephropathy (IgAN) met its primary and key secondary endpoints, with statistically significant and clinically meaningful reductions in proteinuria and stabilization of eGFR through week 36.
The analysts Ryan Deschner and Steven Seedhouse say that the encouraging Phase 2 IgA nephropathy study substantially de-risks the ongoing ...